Overview

Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy

Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the clinical response rate of neoadjuvant chemotherapy with gemcitabine and cisplatin in patients with operable NSCLC
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Cisplatin
Gemcitabine